Effect of enoxaparin on clinical events after percutaneous coronary intervention

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Percutaneous coronary intervention (PCI) is a common procedure for treating coronary artery disease.
• Anticoagulation therapy, including enoxaparin, is often used post-PCI to prevent thrombotic events.
• The necessity and safety of routine anticoagulation after uncomplicated PCI require further investigation.

Purpose of the Study:

• To evaluate the impact of enoxaparin on clinical outcomes, specifically major adverse cardiac and cerebrovascular events (MACCEs), following PCI.
• To compare the incidence of bleeding complications between patients receiving enoxaparin and those not receiving anticoagulation post-PCI.

Main Methods:

• A randomized controlled trial involving 400 patients undergoing uncomplicated PCI.
• Patients were assigned to receive either enoxaparin (anticoagulation group) or no anticoagulant.
• Assessment of MACCEs and bleeding events during hospitalization and at 1 and 12 months post-PCI.

Main Results:

• No significant difference in MACCEs was observed between the enoxaparin and non-anticoagulation groups at any time point (hospitalization, 1 month, 12 months).
• Major bleeding rates were comparable between groups (3.6% vs. 2.1%, P=0.37).
• Minor bleeding events were significantly higher in the enoxaparin group compared to the non-anticoagulation group (29.1% vs. 18.7%, P=0.016).

Conclusions:

• Routine anticoagulation with enoxaparin is not associated with a reduction in MACCEs after uncomplicated PCI.
• Avoiding routine enoxaparin post-PCI can lead to a significant decrease in minor bleeding events.
• These findings suggest that anticoagulation therapy may be unnecessary for patients without complications following PCI.